Tom Kline named co-liaison counsel for Risperdal cases

Serving Philadelphia, Pennsylvania, New Jersey, Delaware, New York & Nationwide

Posted: April 10, 2014

Tom Kline has been named co-liaison counsel by the Court of Common Pleas for Philadelphia for the coordinated litigation involving the drug Risperdal. The anti-psychotic pharmaceutical has been linked to abnormal breast growth in males, including children, adolescents and adults, a condition called gynocomastia. The coordinated litigation in Philadelphia includes about 400 cases. Kline & Specter is serving as lead counsel for a large majority of those cases, joining with the law firm Sheller, PC, which pioneered the Risperdal litigation. Tom Kline is slated to try the first Risperdal case scheduled for July 2014 and involving an autistic child who suffers gynecomastia after using Risperdal. Learn more about Risperdal lawsuits.

Kline & Specter handles cases in Pennsylvania, New Jersey, Delaware and New York. For cases outside those states, Kline & Specter works with local attorneys in each state as applicable.

Kline & Specter, PC only provides legal advice after having entered into an attorney client relationship, which our website specifically does not create. It is imperative that any action taken be done on advice of counsel. Because every case is different, the description of awards and cases previously handled do not guarantee a similar outcome in current or future cases. The firm practices law in New Jersey as Kline & Specter. Super Lawyers, Best Lawyers in America and other organizations that rate attorneys are not designations that have been approved by the State Supreme Courts or the American Bar Association.This website is not intended for viewing or usage by European Union citizens.